Who are Luveris increasing dose's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Orgovyx, Orilissa, Firmagon, Luveris, Cetrotide, Ovidrel.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/luveris-increasing-dose.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Luveris increasing dose — Competitive Intelligence Brief

Luveris increasing dose (Luveris increasing dose) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Gonadotropin. Area: Reproductive Medicine / Fertility.

marketed Gonadotropin LH receptor (LHCGR) Reproductive Medicine / Fertility Small molecule Live · refreshed every 30 min

Target snapshot

Luveris increasing dose (Luveris increasing dose) — University Reproductive Associates. Luveris is a recombinant human luteinizing hormone (LH) that stimulates ovarian steroidogenesis and follicle development in women undergoing assisted reproductive technology.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Luveris increasing dose TARGET	Luveris increasing dose	University Reproductive Associates	marketed	Gonadotropin	LH receptor (LHCGR)
Orgovyx	relugolix	MYOVANT SCIENCES	marketed	Gonadotropin Releasing Hormone Receptor Antagonist [EPC]	Gonadotropin-releasing hormone receptor	2020-01-01
Orilissa	ELAGOLIX	AbbVie	marketed	Gonadotropin Releasing Hormone Receptor Antagonist	Gonadotropin-releasing hormone receptor	2018-01-01
Firmagon	degarelix	Ferring	marketed	Gonadotropin Releasing Hormone Receptor Antagonist	Gonadotropin-releasing hormone receptor	2008-01-01
Luveris	r-hLH	Merck KGaA	marketed	Gonadotropin	Lutropin-choriogonadotropic hormone receptor	2004-01-01
Cetrotide	CETRORELIX	Merck KGaA	marketed	Gonadotropin Releasing Hormone Receptor Antagonist	Gonadotropin-releasing hormone receptor	2000-01-01
Ovidrel	CHORIOGONADOTROPIN ALFA	Merck KGaA	marketed	Gonadotropin	Lutropin-choriogonadotropic hormone receptor	2000-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2036-02-25 — Orgovyx · 10350170 · US
2037-09-29 — Orgovyx · 10449191 · US
2037-09-29 — Orgovyx · 11583526 · US
2037-09-29 — Orgovyx · 11033551 · US
2037-09-29 — Orgovyx · 10786501 · US

Sponsor landscape (Gonadotropin class)

Instituto Valenciano de Infertilidad, IVI VALENCIA · 4 drugs in this class
Sisli Hamidiye Etfal Training and Research Hospital · 3 drugs in this class
Organon and Co · 3 drugs in this class
Fundación Santiago Dexeus Font · 3 drugs in this class
Merck KGaA · 2 drugs in this class
Nina la Cour Freiesleben · 2 drugs in this class
IVI Madrid · 2 drugs in this class
Dunamenti REK Istenhegyi IVF Center · 1 drug in this class
D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology · 1 drug in this class
Azienda USL Modena · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Luveris increasing dose — Competitive Intelligence Brief. https://druglandscape.com/ci/luveris-increasing-dose. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab